Cargando…

Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas

High-grade meningiomas are associated with neuro-cognitive morbidity and have limited treatments. High-grade meningiomas harbor an immunosuppressive tumor microenvironment (TME) and programmed death-ligand 1 (PD-L1) expression may contribute to their aggressive phenotype. Here, we present the result...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brastianos, Priscilla K., Kim, Albert E., Giobbie-Hurder, Anita, Lee, Eudocia Quant, Wang, Nancy, Eichler, April F., Chukwueke, Ugonma, Forst, Deborah A., Arrillaga-Romany, Isabel C., Dietrich, Jorg, Corbin, Zachary, Moliterno, Jennifer, Baehring, Joachim, White, Michael, Lou, Kevin W., Larson, Juliana, de Sauvage, Magali A., Evancic, Kathryn, Mora, Joana, Nayyar, Naema, Loeffler, Jay, Oh, Kevin, Shih, Helen A., Curry, William T., Cahill, Daniel P., Barker, Fred G., Gerstner, Elizabeth R., Santagata, Sandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921328/ https://www.ncbi.nlm.nih.gov/pubmed/35289329 http://dx.doi.org/10.1038/s41467-022-29052-7

Ejemplares similares

Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
por: Brastianos, Priscilla K., et al.
Publicado: (2021)

Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens
por: Brastianos, Priscilla K., et al.
Publicado: (2017)

62. PRESENCE OF EXTRACRANIAL TUMORS INFLUENCES RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN A PRE-CLINICAL MODEL OF MELANOMA BRAIN METASTASIS
por: Nayyar, Naema, et al.
Publicado: (2020)

Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice
por: Chukwueke, Ugonma N, et al.
Publicado: (2019)

Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors
por: Rahma, Osama E, et al.
Publicado: (2022)

Detection of Leptomeningeal Disease Using Cell-Free DNA From Cerebrospinal Fluid
por: White, Michael D., et al.
Publicado: (2021)

Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases
por: Prakadan, Sanjay M., et al.
Publicado: (2021)

Author Correction: Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases
por: Prakadan, Sanjay M., et al.
Publicado: (2021)

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRAS(G12C)-Mutant Non–Small Cell Lung Cancer
por: Sabari, Joshua K., et al.
Publicado: (2022)

Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors
por: Zhu, Li, et al.
Publicado: (2019)

Craniopharyngiomas, including Recurrent Cases, Lack TERT Promoter Hotspot Mutations
por: FUJIO, Shingo, et al.
Publicado: (2021)

Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome
por: Nishino, Mizuki, et al.
Publicado: (2014)

INNV-40. REAL WORLD INTEGRATION OF THE NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN CLINICAL PRACTICE IN PATIENTS WITH IDH-WT GBM
por: Lim-Fat, Mary Jane, et al.
Publicado: (2021)

Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma
por: Shih, David J. H., et al.
Publicado: (2020)

The Protein Kinase C Inhibitor Enzastaurin Exhibits Antitumor Activity against Uveal Melanoma
por: Wu, Xinqi, et al.
Publicado: (2012)

Association of Type I Neurons Positive for NADPH-Diaphorase with Blood Vessels in the Adult Monkey Corpus Callosum
por: Rockland, Kathleen S., et al.
Publicado: (2012)

Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
por: Regan, Meredith M, et al.
Publicado: (2011)

A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4
por: Williams, Erik A., et al.
Publicado: (2023)

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate
por: Andronesi, Ovidiu C., et al.
Publicado: (2018)

Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence
por: Christ, Sebastian M., et al.
Publicado: (2023)

The benefits of steroids versus steroids plus antivirals for treatment of Bell’s palsy: a meta-analysis
por: Quant, Eudocia C, et al.
Publicado: (2009)

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
por: Keenan, Tanya E., et al.
Publicado: (2021)

Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
por: Elias, Rawad, et al.
Publicado: (2018)

Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor
por: Alvarez-Breckenridge, Christopher, et al.
Publicado: (2017)

OR19-5 The Impact Of High Dose Glucocorticoids On The Outcome Of Immune Checkpoint Inhibitor-related Thyroid Disorders And The Baseline TSH As A Predictive Biomarker
por: Min, Le, et al.
Publicado: (2019)

Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma
por: Alexander, Brian M., et al.
Publicado: (2019)

Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
por: Lee, Eudocia Q., et al.
Publicado: (2019)

Yoga for chronic chemotherapy-induced peripheral neuropathy pain: a pilot, randomized controlled trial
por: Knoerl, Robert, et al.
Publicado: (2021)

Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
por: Fiorelli, Alfonso, et al.
Publicado: (2019)

Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma
por: Zukotynski, Katherine, et al.
Publicado: (2014)

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma
por: Arrillaga-Romany, Isabel, et al.
Publicado: (2017)

Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma
por: Zhou, Jun, et al.
Publicado: (2011)

Qigong Mind-Body Exercise as a Biopsychosocial Therapy for Persistent Post-Surgical Pain in Breast Cancer: A Pilot Study
por: Osypiuk, Kamila, et al.
Publicado: (2020)

Bamlanivimab Efficacy in Older and High-BMI Outpatients With COVID-19 Selected for Treatment in a Lottery-Based Allocation Process
por: Rubin, Emily B, et al.
Publicado: (2021)

Performance of a Triage Protocol for Monoclonal Antibodies in a Mixed Vaccinated and Unvaccinated Cohort of COVID-19 Patients Treated With Intravenous Infusion or Subcutaneous Injection
por: Rubin, Emily B, et al.
Publicado: (2022)

Evaluating hematologic parameters in newly diagnosed and recurrent glioblastoma: Prognostic utility and clinical trial implications of myelosuppression
por: Deng, Davy, et al.
Publicado: (2023)

EGFR mutant locally advanced non-small cell lung cancer is at increased risk of brain metastasis
por: Mitra, Devarati, et al.
Publicado: (2019)

MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastoma
por: Talati, Pratik, et al.
Publicado: (2021)

NEIM-11 DEUTERIUM METABOLIC IMAGING (DMI) DETECTS A LARGER WARBURG EFFECT IN HIGH-GRADE BRAIN TUMORS AND IN IDH WILD TYPE GLIOMAS
por: Kim, Lauren, et al.
Publicado: (2023)

Pembrolizumab
por: Khoja, Leila, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7tvuf3i28v45uhcmmk3r02eiq6